The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmetzer, O.
Right arrow Articles by Pezzutto, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmetzer, O.
Right arrow Articles by Pezzutto, A.
The Journal of Immunology, 2005, 174: 942-952.
Copyright © 2005 by The American Association of Immunologists

Quality of Recombinant Protein Determines the Amount of Autoreactivity Detected against the Tumor-Associated Epithelial Cell Adhesion Molecule Antigen: Low Frequency of Antibodies against the Natural Protein

Oliver Schmetzer1,*,{dagger}, Gerhard Moldenhauer{ddagger}, Rainer Riesenberg§, José Ricardo Pires||, Peter Schlag and Antonio Pezzutto*,{dagger}

* Molecular Immunotherapy, Max Delbrück Centrum for Molecular Medicine, Berlin, {dagger} Department of Hematology and Oncology, Charité, Humboldt University, Berlin, {ddagger} German Cancer Research Center, Division of Molecular Immunology (D050), Heidelberg, § Ludwig Maximilians University Muenchen, University Clinic Grosshadern, Department of Urology, Tumor Immunology Group, Munich, Department of Surgical Oncology, Robert Rössle Klinik, Charité, Humboldt University, Berlin, Germany; and || Universidade Federal do Rio de Janeiro, Departamento de Bioquimica Medica, Rio de Janeiro, Brazil

The human epithelial cell adhesion molecule (EpCAM) is expressed on normal epithelial cells and is overexpressed in most carcinomas. EpCAM-targeted immunotherapy has been tried in several clinical studies. High titers of autoantibodies against EpCAM have been reported by different authors. We have generated large amounts of purified protein in S2 Drosophila cells (S2-EpCAM) with a purity of >96%. In contrast, the protein produced in baculovirus-dependent systems (baculo-EpCAM) that has been used in previous studies shows a purity of 79%. 1H nuclear magnetic resonance spectrum of S2-EpCAM is typical of folded protein, whereas the baculo-EpCAM sample shows a spectrum corresponding to a partially unfolded protein. Using S2-EpCAM, denatured S2-EpCAM, and baculo-EpCAM, we measured EpCAM Abs of different isotypes in the serum of healthy controls and cancer patients. We found Ab titers against EpCAM in a much lower percentage of sera as published previously, and support the hypothesis that Ab reactivity in some published studies might be due to reactivity against denatured protein, to contaminating proteins in the baculovirus preparations, and to reactivity with BSA. Tetanus toxoid-reactive IgG Abs are present in 1000-fold higher titers compared with EpCAM-reactive Abs. Only IgA Abs were found in higher proportions and in higher concentrations than tetanus toxoid-specific Abs. Our study shows that EpCAM only rarely induces autoantibodies against native protein and emphasizes the importance of using extremely purified Ag preparations when evaluating Abs against tumor-associated Ags.




This article has been cited by other articles:


Home page
Ann OncolHome page
C Chapman, A Murray, J Chakrabarti, A Thorpe, C Woolston, U Sahin, A Barnes, and J Robertson
Autoantibodies in breast cancer: their use as an aid to early diagnosis
Ann. Onc., May 1, 2007; 18(5): 868 - 873.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. J.E. Arlt, I. Novak-Hofer, D. Gast, V. Gschwend, G. Moldenhauer, J. Grunberg, M. Honer, P. A. Schubiger, P. Altevogt, and A. Kruger
Efficient Inhibition of Intra-Peritoneal Tumor Growth and Dissemination of Human Ovarian Carcinoma Cells in Nude Mice by Anti-L1-Cell Adhesion Molecule Monoclonal Antibody Treatment
Cancer Res., January 15, 2006; 66(2): 936 - 943.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.